Navigation and service

Annual Report 2015/16 of the Paul-Ehrlich-Institut published

Biomedicines are undergoing a rapid development – this is accompanied by the scientific and regulatory activities of the Paul-Ehrlich-Institut as a leading medicines authority in Europe. The Annual Report 2015/16 provides information on the strategy, marketing authorisation, testing and current research activities at the PEI in a national, European, and world-wide setting.

more: Annual Report 2015/16 of the Paul-Ehrlich-Institut published …

VAC2VAC – Vaccine batch to vaccine batch comparison by consistency testing

After the VAC2VAC project was started in March 2016, the first annual meeting was held at the Paul-Ehrlich-Institut on 9 and on 10 March 2017. VAC2VAC is a consortium composed of both public and private members. It consists of 20 partners including pharmaceutical manufacturers of vaccines for human and veterinary use, academic institutes, and regulatory authorities.

more: VAC2VAC – Vaccine batch to vaccine batch comparison by consistency testing …

Innovative medicines for Europe – Dr Martina Schüssler-Lenz of the Paul-Ehrlich-Institut elected chair of the EMA Committee for Advanced Therapies

In February this year, Dr Martina Schüssler-Lenz, clinical assessor at Division Medical Biotechnology of the Paul-Ehrlich-Institut (PEI) was elected chairperson of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA). Dr Schüssler-Lenz is a physician trained in internal medicine, and has specific expertise in the medical and regulatory field.

more: Innovative medicines for Europe – Dr Martina Schüssler-Lenz of the Paul-Ehrlich-Institut elected chair of the EMA Committee for Advanced Therapies …

This Page

Additional Information